For many scientists, the pandemic changed research
Share Now on:
Over the past year, while some scientists turned their attention to COVID-19 and creating vaccines to fight it, most others had to pause their research — and re-imagine how to do it. Isabella Rauch, an immunologist at Oregon Health & Science University in Portland, has mostly worked from home. Now, she occasionally works in her lab.
But the lab where Rauch studies how pathogens enter the body through the intestines looks different these days. All the machinery — incubators, freezers, scanners — used by multiple people were located in one common space before the pandemic began.
“But we really tried to make it possible for people to access these machines now during their work without having to cross someone else’s path or come close to someone else that’s doing their work,” Rauch said.
It’s taken a while to get things up and running. She had to organize social-distance scheduling for researchers, breed new mice for experiments, thaw out frozen cells and then figure out how to virtually share images of those cells under a microscope.
Her lab now operates at 70% capacity. And because of all the restrictions, the spontaneity that can cultivate scientific insight is lost.
“It’s less fun, I have to say. Like, for me the big part of the science is discussing the science with other people, getting excited about projects,” Rauch said.
And it may be harder to do that next project. Rauch’s lab is a young one. So every experiment, all of her research, counts in terms of getting funding for future projects. But her work has been interrupted, scaled back and delayed.
“It’s definitely going to hurt us applying for bigger grants in comparison to more established labs,” she said.
Finances are also a concern for John Roll. He’s dean of research at Washington State University’s medical school. He’s been spending a lot of time strategizing how to keep the research going and how to fund it with all the other financial challenges facing higher education.
One possibility? Reaching out to the private sector to underwrite research.
“Those types of public-private partnerships may become a little more common and actually a very pragmatic way for university-based researchers and industry to serve mutual benefits,” Roll said.
Funding is also the big question for Dr. Kevin Sheth. He’s a neurologist at Yale who does clinical trials on traumatic brain disorders. One of his studies involves 120 research sites across the country. Over the summer, about half of the sites were up and running, with modifications such as electronic consent, virtual follow-up and remote assessments. But the surge in COVID-19 cases in the fall took a toll.
“Many of the physicians who are investigators and researchers simply don’t have the time and the bandwidth and the staff to conduct clinical trial activities in high-quality and safe ways because they’re pulled for emergency clinical care,” Sheth said.
So his project is behind schedule — Sheth expected his research to take three to five years, and now it’s looking more like five to eight. But there isn’t any more funding. When asked if the delays will make the science suffer, he responded: “Yes it suffers. I mean absolutely.”
But Sheth is an optimist. Trying to do non-COVID-19 science during the pandemic, he said, “does push us to figure out how to become more efficient, how to become more cost-effective and how to ask and answer new scientific questions that we wouldn’t have otherwise been compelled to, even in our existing projects.”
COVID-19 Economy FAQs
What’s the outlook for vaccine supply?
Chief executives of America’s COVID-19 vaccine makers promised in congressional testimony to deliver the doses promised to the U.S. government by summer. The projections of confidence come after months of supply chain challenges and companies falling short of year-end projections for 2020. What changed? In part, drugmakers that normally compete are now actually helping one another. This has helped solve several supply chain issues, but not all of them.
How has the pandemic changed scientific research?
Over the past year, while some scientists turned their attention to COVID-19 and creating vaccines to fight it, most others had to pause their research — and re-imagine how to do it. Social distancing, limited lab capacity — “It’s less fun, I have to say. Like, for me the big part of the science is discussing the science with other people, getting excited about projects,” said Isabella Rauch, an immunologist at Oregon Health & Science University in Portland. Funding is also a big question for many.
What happened to all of the hazard pay essential workers were getting at the beginning of the pandemic?
Almost a year ago, when the pandemic began, essential workers were hailed as heroes. Back then, many companies gave hazard pay, an extra $2 or so per hour, for coming in to work. That quietly went away for most of them last summer. Without federal action, it’s mostly been up to local governments to create programs and mandates. They’ve helped compensate front-line workers, but they haven’t been perfect. “The solutions are small. They’re piecemeal,” said Molly Kinder at the Brookings Institution’s Metropolitan Policy Program. “You’re seeing these innovative pop-ups because we have failed overall to do something systematically.”
News and information you need, from a source you trust.
In a world where it’s easier to find disinformation than real information, trustworthy journalism is critical to our democracy and our everyday lives. And you rely on Marketplace to be that objective, credible source, each and every day.
This vital work isn’t possible without you. Marketplace is sustained by our community of Investors—listeners, readers, and donors like you who believe that a free press is essential – and worth supporting.